|
Cancer | CD10 level | Prognosis | References |
|
Prostate cancer | Decreased/total loss of CD10 expression | Androgen-independent progression | [48, 49] |
Prostate cancer | High level of CD10 | Aggressive phenotype, higher malignancy rate, larger metastases, early death | [33, 50] |
Breast cancer | Stromal CD10 expression | Poor prognosis, estrogen receptor negativity, high grade | [35, 43] |
Melanomas | High CD10 expression | Advanced stage, higher metastasis | [44, 45] |
Follicular papillary thyroid cancer | High CD10 expression | Bad | [46] |
Papillary thyroid cancer | High CD10 expression | Advanced stage | [47] |
Adenocarcinoma of stomach and colon | Decreased CD10 expression | Poor differentiation | [13] |
Head and neck squamous cell carcinoma | Increased CD10 expression | Therapeutic resistance | [44] |
Colorectal cancer | Increased CD10 expression | Higher invasion | [25] |
Colorectal cancer | Serum CD10 expression | Liver metastasis | [28] |
Esophageal squamous cell carcinoma | Upregulated CD10 expression | Poor disease-free survival and overall survival | [29] |
Pancreatic endocrine tumors | Membranous expression of CD10 | Poor differentiation, high proliferative index, low microvascular density, large tumor size, metastasis, poor survival | [36] |
Cervical carcinoma | Decreased CD10 expression | Higher proliferation and invasion | [52] |
Ovarian carcinoma | Increased CD10 expression | Suppressing progressive potential | [53] |
Gastric carcinoma | Stromal cells CD10 expression | Differentiated carcinoma, high depth of invasion, lymph node metastasis | [40] |
|